ARTICLE
15 January 2020

The Bio/Pharma Beat - January 2020

SP
Squire Patton Boggs LLP

Contributor

Squire Patton Boggs is a full service global law firm providing insight at the point where law, business and government meet, giving you a voice, supporting your ambitions and achieving successful outcomes.

With a multidisciplinary team of over 1,500 lawyers in over 40 offices across four continents, we are well-established geographically with strong local and regional positions in North America, Europe, Asia Pacific, the Middle East and Latin America, and our practice experience spans all key sectors.

We would like to share with you the Bio/Pharma Beat, our monthly newsletter reporting on the patent law developments you should know in biotech, biologics and pharmaceutical cases, legislation and federal agency actions.
United States Food, Drugs, Healthcare, Life Sciences
Squire Patton Boggs LLP are most popular:
  • within Food, Drugs, Healthcare, Life Sciences, Finance and Banking and Immigration topic(s)
  • in United States

We would like to share with you the Bio/Pharma Beat, our monthly newsletter reporting on the patent law developments you should know in biotech, biologics and pharmaceutical cases, legislation and federal agency actions. This month's issue covers relevant news from December 2019, including:

  • The Solicitor General, on behalf of the US, asserts that the Supreme Court's Section 101 precedent creates "substantial uncertainty" requiring clarification
  • The Federal Circuit holds that there is no single entity requirement for infringement under section 271(g)
  • A district court holds that, under certain circumstances, an anticipatory reference is not necessarily "but-for" material under an inequitable conduct analysis

Download: The Bio/Pharma Beat - January 2020

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

[View Source]

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More